Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941063 | 0.91 | KMT2A (0.64) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941089 | 0.90 | KMT2A (0.83) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941288 | 0.89 | MAPT (0.77) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941068 | 0.88 | KMT2A (0.66) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941216 | 0.88 | KMT2A (0.60) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL17444569 | 0.82 | KDM4E (0.70) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941127 | 0.82 | KMT2A (0.78) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941145 | 0.81 | RAB9A (0.66) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941186 | 0.81 | MAPT (0.72) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL18941134 | 0.81 | MAPT (0.66) | KMT2AMEN1RAB9AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | KMT2A 2215/4885MEN1 3325/4885RAB9A 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.